ARTICLE | Finance


Affymax hopes new safety data firms up case for peginesatide NDA in dialysis

May 2, 2011 7:00 AM UTC

Shares of Affymax Inc. (NASDAQ:AFFY) edged up last week after reporting new analyses of its Phase III peginesatide data that bolster the case for use of the ESA in the dialysis setting and keep the company on course to submit an NDA this quarter.

Two of the presentations provided looks at the individual EMERALD 1 and 2 trials and included secondary endpoint data on both safety and maintenance of hemoglobin levels within a target range for peginesatide versus epoetin (see B13)...